N/A N=364 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Lymphoma · Digestive System Diseases · Ovarian Diseases
Primary: Number of Participant Deaths — 56 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Chemotherapy-induced Nausea and Vomiting
Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants
N/A N=128 Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence
Medication Adherence
Primary: Medication Adherence at Baseline and 6-month Follow-up Period — 59.4; 55.95 units on a scale
N/A N=181 Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer
Adherence to Medication Regime · Cancer
Primary: Self-reported Difficulties With Adherence on Any of the Four MMAS-4 Items in the Past Week — 11; 20 Participants — p=0.186
N/A N=16 Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Colon Cancer · Rectal Cancer
Primary: Patient Retention and Engagement With the MyChemoCare Application — 15; 12 Participants
Phase 2 N=105 Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Cancer · Influenza Viral Infections
Primary: The Geometric Mean Titer (GMT) of High-dose Influenza Vaccine vs the Standard Trivalent Influenza Vaccine in Adult Subjects on Chemotherapy Who Are Less Than 65 Years…
Phase 2 N=30 Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Melanoma
Primary: Cumulative Participants Response to Palonosetron — 85; 139; 44; 72 episodes of nausea/vomiting
N/A N=186 Improving Informed Consent for Palliative Chemotherapy
Metastatic Colorectal Cancer · Metastatic Pancreatic Cancer · Unresectable Pancreatic Cancer
Primary: Number of Patients With Accurate Understanding of Chemotherapy Benefits — 39; 39; 30; 31 Participants
Phase 2 N=59 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
N/A N=20 Acupuncture on Chemotherapy-induced Peripheral Neuropathy
Randomized Controlled Trial · Breast Cancer · Chemotherapy-induced Peripheral Neuropathy
Primary: The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF) — 3.10; 3.10; 1.72; 3.50 score on a scale
Phase 4 N=33 Chemotherapy for Patients With Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR]) — 0.182 proportion of responders
N/A N=7 Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation
Phase 2 N=13 Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Osteosarcoma · Nephrotoxicity · Ototoxicity
Primary: Change in Urinary Biomarkers of Acute Kidney Injury (AKI) Between Pre-Treatment (Baseline), After CISplatin (C) Treatments, and After HDTMX Treatments — 1.7; 1.7; 2.1…
N/A N=52 Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Colorectal Cancer · Gastric Cancer · Esophageal Cancer
Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
N/A N=1,007 Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Chemotherapy-induced Febrile Neutropenia
Primary: Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia — 73.4; 88.3; 41.1; 25.0 percentage of investigators
Phase 2 N=85 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Chemotherapy-Induced Nausea and Vomiting · Ovarian Cancer
Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…
N/A N=43 Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Ovarian Cancer · Peritoneal Primary Cancer · Fallopian Tube Cancer
Primary: Quality of Life Comparison - Average FACT-O Scoring in Chemotherapy Alone vs. Chemotherapy Plus Complementary Alternative Medicine (CAM) — 143; 152; 154; 152 Scores on a…
Phase 2 N=7 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
N/A N=23 Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Change in the Sensory Neuropathic Pain Score as Measured by the European Organization of Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire…
N/A N=19 Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Breast Neoplasm · Physical Activity
Primary: Acceptability: Percent of Eligible Patients That Provide Consent and Are Enrolled in the Study. — 19 Participants
Phase 2 N=50 Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Venous Thormboembolism
Primary: Total Number of Venous Thromboembolic Events (VTE) in Standard Dose Enoxaparin Arm at 17 Days — 2 participants
Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
N/A N=446 Post-chemotherapy Symptom Management SMART
Cancer
Primary: Symptom Severity Index- Comparison of Two Groups Created by First Randomization — 24.53; 25.86 score on a scale — p=.31
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 2 N=103 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) — 7.5; 0; 3.1 percentage of participants
N/A N=20 Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Lymphoma
Primary: Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group — 300; 250 ug/mL*hr
N/A N=12 Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy
Peripheral Neuropathies
Primary: Prevention of Peripheral Neuropathy During Taxane Chemotherapy — 7.28 score on a scale
N/A N=134 Care Partners: Web-based Support for Caregivers of Veterans Undergoing Chemotherapy
Cancer
Primary: Summed Symptom Severity — 23.2; 19.9 units on a scale — p=0.030